U.S. Communications Stock News

NYSE:XPEV
NYSE:XPEVAuto

US Stock Market Today: S&P 500 Futures Dip as Shutdown Concerns Weigh on Sentiment

The Morning Bull - US Market Morning Update Tuesday, Nov, 11 2025 US stock futures are slightly lower this morning, with S&P 500 futures down about 0.2%, as investors weigh progress on a potential US government funding bill. The Senate has advanced legislation to end a historic 41-day shutdown, with a final vote still pending in the House. This means basic government services could be restored soon, but any delay could keep markets on edge. Meanwhile, China’s vehicle market powered higher,...
NYSE:SCI
NYSE:SCIConsumer Services

What Does Service Corporation International’s Recent Expansion Mean for Its 2025 Valuation?

Wondering if Service Corporation International is trading for a bargain or already priced for perfection? You are not alone, and getting a handle on fair value is crucial before you commit your cash. Shares have drifted a bit this year, rising 3.5% year-to-date but sliding 5.9% over the past 12 months, so sentiment around future growth and risk could be shifting. Recent headlines have focused on Service Corporation International's expansion into new geographic markets and a series of...
NYSE:FBP
NYSE:FBPBanks

Does First BanCorp’s Recent Price Dip Signal a Hidden Opportunity in 2025?

Ever looked at First BanCorp and wondered if the price on the screen genuinely matches what the business is worth? You are not alone; deciphering value in banks like this can be both fascinating and rewarding. Over the past year, the stock has dipped slightly by 3%. Zooming out to five years, it has risen by 187.3%, suggesting significant growth potential and shifting market sentiment. First BanCorp has found itself in investor headlines lately as regional banks respond to industry trends...
NasdaqGS:FOXF
NasdaqGS:FOXFAuto Components

Can Fox Factory (FOXF) Balance Earnings Pressures With Innovation in Suspension Technology?

Earlier this month, Fox Factory Holding Corp. reported third quarter 2025 results, updating its full-year net sales guidance to US$1.445 billion–US$1.475 billion and announcing the launch of its advanced Live Valve semi-active suspension system for the aftermarket truck and Jeep segment, available in early 2026. This combination of a new product unveiling and revised financial outlook reflects the company’s emphasis on innovation amid ongoing operating challenges in earnings...
NYSE:PLYM
NYSE:PLYMIndustrial REITs

Plymouth Industrial REIT (PLYM): Is the Recent 50% Rally Reflected in Its Current Valuation?

Plymouth Industrial REIT (PLYM) has quietly delivered a 5% gain over the past month, continuing a steady climb that has seen shares rise nearly 50% in the past 3 months. With recent annual revenue growth and a long-term positive trend, investors are watching for what is next. See our latest analysis for Plymouth Industrial REIT. Momentum has clearly been building for Plymouth Industrial REIT, with a recent 1-month share price return of nearly 5 percent adding to a remarkable 50 percent surge...
NasdaqGS:DNUT
NasdaqGS:DNUTHospitality

Can Krispy Kreme’s (DNUT) Menu Overhaul Reshape Its Brand Appeal and Competitive Edge?

Earlier this month, Krispy Kreme launched a refreshed doughnut menu, adding nine new flavors and expanding its everyday offerings to 16 full-sized options, supported by a marketing campaign featuring Grammy-winning artist Montell Jordan. This substantial menu revamp, developed over a year and inspired by customer feedback and trends, marks one of the company’s most extensive product expansions to date. We'll explore how this major menu expansion and high-profile marketing push could...
NasdaqCM:AKBA
NasdaqCM:AKBABiotechs

A Look at Akebia Therapeutics (AKBA) Valuation Following Q3 Profit and New Vafseo Clinical Data

Akebia Therapeutics (AKBA) just posted third quarter 2025 earnings, swinging from a net loss to net profit as a result of much higher revenue. Investors are watching closely because this marks a financial turnaround for the company. See our latest analysis for Akebia Therapeutics. Akebia’s share price has taken a hit recently. Even after swinging to profit this quarter, it fell 18% in the past day and is down 39% over the last month as investors digested mixed clinical trial updates and...